Answers are grounded in this paper and cite their sources.
Objective: Chronic wounds represent a significant clinical burden, driven by persistent inflammation and extracellular matrix degradation that impair healing across etiologies. Diabetes is a known risk factor; however, similar biological barriers exist in nondiabetic wounds. Advanced therapies are often focused on diabetic populations, yet effective treatments that address shared healing impairments across both diabetic and nondiabetic wounds remain limited. Approach: This multicenter pooled analysis included 197 chronic wounds treated with autologous whole blood clot (AWBC). Outcomes were compared between diabetic (56%) and nondiabetic patients. Percent area reduction (PAR) was assessed at weeks 4, 12, and 20, and complete healing rates were evaluated at weeks 12 and 20. Results: Progress toward healing was observed across all wound types treated with AWBC. By week 20, median PAR improved to 96.5–100% in diabetic and 80–100% in nondiabetic wounds, with no significant differences. In a subgroup analysis, venous-treated wounds in diabetic patients showed better outcomes at week 12 than nondiabetic patients ( p = 0.039). In contrast, for trauma wounds, nondiabetic patients showed greater improvement than diabetic patients at weeks 4 and 12 ( p = 0.014 and 0.029, respectively). After adjustment for wound characteristics and age, diabetic status was not significantly associated with complete closure at week 20 (odds ratio, 1.91; 95% confidence interval, 0.75–4.87; p = 0.17). Innovation: AWBC is a point-of-care therapy that forms a fibrin-rich, biologically active scaffold, delivering cells and growth factors, intended to support the wound-healing cascade. Discussion: Wound healing was observed in both diabetic and nondiabetic patients treated with AWBC, with no significant overall differences in complete healing rates. Although subgroup differences were observed in venous leg ulcers and trauma wounds, no overall differences in healing were detected by diabetic status, suggesting that AWBC may be considered in both populations.
No takes yet. Share an insight, caveat, or question.
Snyder et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: